We recently described a novel genetically engineered VV based on a thymidine kinase (TK)- deleted, N1L gene-deleted VV, VVLΔTKΔN1L, in which the TK and N1L gene deletions were shown to enhance not only tumor selectivity and safety, but also anti-tumor immune responses (25). Here, TKT is linked to neoplasm.